NCT05857085View on ClinicalTrials.gov

Novel Therapeutics and Endothelial Dysfunction in T1DM Patients

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 15, 2021

Primary Completion Date

March 10, 2022

Study Completion Date

April 20, 2023

Conditions

Endothelial DysfunctionDiabetes Mellitus, Type 1BiomarkersEndothelial Progenitor CellsSGLT 2 InhibitorsIncretinsGlucose ExcursionsFMDFPFArterial Stiffness

Interventions

DRUG

Semaglutide Pen Injector [Ozempic]

GLP 1 agonist

DRUG

Empagliflozin 10 MG

SGLT 2 inhibitor

Trial Locations (1)

3000

General Hospital Celje, Celje

All Listed Sponsors

lead

General and Teaching Hospital Celje

OTHER

NCT05857085 - Novel Therapeutics and Endothelial Dysfunction in T1DM Patients | Biotech Hunter | Biotech Hunter